Genetic Testing for Hereditary Breast and/or Ovarian Cancer

Transcription

1 Genetic Testing for Hereditary Breast and/or Ovarian Cancer I. Policy University Health Alliance (UHA) will reimburse for genetic testing for hereditary breast and/or ovarian cancer when they are determined to be medically necessary and when they meet the medical criteria guidelines (subject to limitations and exclusions) indicated below. II. Criteria/Guidelines A. Genetic testing for BRCA1 and BRCA2 1. Genetic testing for breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) mutations in cancer-affected individuals is covered (subject to Limitations/Exclusions and Administrative Guidelines) under any of the following circumstances: a. Women who are affected with breast cancer, ovarian cancer, cancer of the fallopian tube, or primary peritoneal cancer, and are from families with a high risk of BRCA1 or BRCA2 mutation as defined in the Policy Guidelines, OR; b. Women who do not have a known family history of breast, epithelial ovarian, fallopian tube, or primary peritoneal cancer, but are affected with any of the following: i. Early onset breast cancer (diagnosed at 45 years or younger or premenopausal); ii. Two breast primary cancers with the first cancer diagnosis occurring prior to age 50 years; iii. Triple negative breast cancer (neither express estrogen receptor and progesterone receptor, nor overexpress HER2) diagnosed at younger than age 60; iv. Epithelial ovarian / fallopian tube / primary peritoneal cancer at any age, OR; c. Women affected with both breast cancer and either ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, OR; d. Men affected with breast cancer at any age, OR; e. Those affected with breast, epithelial ovarian, fallopian tube, or primary peritoneal cancer and who are from an ethnic background, e.g., Ashkenazi Jewish descent, associated with deleterious founder mutations. 2. Genetic testing for BRCA1 and BRCA2 mutations of unaffected (no personal history of cancer) adults is covered only (subject to Limitations/Exclusions and Administrative Guidelines) a. After the genetic risk assessment (requiring prior authorization) and only when: i. The unaffected individuals (male or female) are from families with a known BRCA1 or BRCA2 mutation, OR; ii. The unaffected individuals are from families with a high risk of BRCA1 or BRCA2 mutation based on a family history (see Policy Guidelines), and where it is not possible to test an affected family member for a mutation; Page 1

2 iii. The unaffected individuals are in populations at risk for specific founder mutations due to ethnic background, e.g., Ashkenazi Jewish descent, and with one or more relatives with breast, epithelial ovarian, fallopian tube, or primary peritoneal cancer at any age; iv. And the genetic counselor concurs with the testing. b. Testing for genomic rearrangements of the BRCA1 and BRCA2 genes (BART testing) is covered (subject to Limitations/Exclusions and Administrative Guidelines) in patients who meet criteria for BRCA testing, whose testing for point mutations is negative. B. Genetic Risk Assessments: 1. A genetic risk assessment is covered (subject to Limitations and Administrative Guidelines) in cancer-affected individuals with: a. Early onset breast cancer (<45 years old or premenopausal); b. A first or second degree relative with a BRCA-related cancer (breast, ovarian, fallopian tube or primary peritoneal cancer); c. A first or second degree relative with a BRCA mutation. 2. A genetic risk assessment is covered (subject to Limitations and Administrative Guidelines) in unaffected (no personal history of cancer) individuals with: a. A first degree relative with early onset breast cancer (<45 years old or premenopausal); b. Two affected first or second degree relatives with a BRCA-related cancer (breast, ovarian, fallopian tube or primary peritoneal cancer); c. A first or second degree relative with a BRCA mutation. 3. For asymptomatic individuals who meet above criteria, UHA requires pre-test genetic risk assessment (one visit with prior authorization) as a condition for approval of genetic testing. C. Genetic risk assessments must also meet the following: 1. Services must be conducted by a properly certified/licensed and credentialed genetic specialist (i.e., board-certified medical geneticist (MD), board-certified clinical geneticist (PhD), board-certified genetic counselor (MS and/or CGC), or licensed advanced practice registered nurse in genetics (APRN); 2. Services must be conducted in a face-to-face consultation and a subsequent consultation letter or report must be submitted to the treating physician. D. One risk assessment visit after genetic testing is covered for patients who qualified for predictive genetic testing under the following conditions: 1. Pre-test genetic risk assessment was conducted and covered as part of prior authorization for selected genetic tests as stated above; 2. The patient qualified and received the ordered genetic test according to the pre-test assessment; 3. A CLIA-certified laboratory submits a viable claim for the completed genetic test. Page 2

3 E. NOTE: This UHA payment policy is a guide to coverage, the need for prior authorization and other administrative directives. It is not meant to provide instruction in the practice of medicine and it should not deter a provider from expressing his/her judgment. Even though this payment policy may indicate that a particular service or supply is considered covered, specific provider contract terms and/or member individual benefit plans may apply, and this policy is not a guarantee of payment. UHA reserves the right to apply this payment policy to all UHA companies and subsidiaries. UHA understands that opinions about and approaches to clinical problems may vary. Questions concerning medical necessity (see Hawaii Revised Statutes 432E-1.4) are welcome. A provider may request that UHA reconsider the application of the medical necessity criteria in light of any supporting documentation. III. Limitations/Exclusions A. An affected family member should be tested first whenever possible. Should a BRCA mutation be found in an affected family member, the DNA from the unaffected family member can be tested specifically using a tailored study for the same mutation of the affected family member without having to sequence the entire gene. B. Genetic testing for unaffected individuals (of both the general population and of potentially high-risk ethnic populations) without a family history suggesting increased risk of BRCA mutation is not covered. C. Genetic testing in minors for BRCA1 and BRCA2 mutations is not covered. D. Genetic testing for BRCA1 and BRCA2 mutations is not covered for assessment of risk of other cancers including but not limited to pancreatic, prostate and colon cancer. E. Benefits are provided only for UHA members; benefits are not provided for family members without current UHA coverage. F. Unless they meet the criteria above, genetic testing for either those affected with breast, ovarian, fallopian tube, or primary peritoneal cancer or for unaffected individuals is not covered as it has not been shown to improve health outcomes. G. Testing for CHEK2 genetic abnormalities (mutations, deletions, etc.) is not covered in affected and unaffected patients with breast cancer irrespective of family history as it has not been shown to improve health outcomes. H. Laboratories that conduct genetic testing must be CLIA certified. I. Genetic counseling is not a separately covered benefit. See Criteria/Guidelines for coverage of genetic risk assessment. J. Repeat BRCA1 or BRCA2 mutation testing is not covered. K. Testing for one or more single nucleotide polymorphisms (SNPs) to predict an individual's risk of breast cancer is not covered as it has not been shown to improve health outcomes. IV. Administrative Guidelines A. Prior authorization is required for the following: 1. Genetic risk assessments; 2. Genetic testing for inherited BRCA1 or BRCA2 mutations. Page 3

4 B. To request prior authorization, please go to UHA s website: and submit it: Via Fax: Via Mail: UHA Health Care Services 700 Bishop Street, Suite 300 Honolulu, HI ICD-9 Code C. The information received should include the member s family history and a brief summary as to why the genetic test is needed. D. If prior authorization is not obtained, the member will not be held responsible for payment of denied services unless UHA s Advance Financial Notice form is completed and signed. This form is available via UHA s website: E. Applicable Codes Malignant neoplasm of specified parts of peritoneum Malignant neoplasm of female breast Malignant neoplasm of male breast Malignant neoplasm of ovary Malignant neoplasm of fallopian tube Carcinoma in situ of breast Carcinoma in situ, vagina Carcinoma in situ, vulva V10.3 Personal history of malignant neoplasm of breast V10.43 Personal history of malignant neoplasm of ovary V16.3 Family history of malignant neoplasm of breast V16.41 Family history of malignant neoplasm of ovary V16.8 Family history of malignant neoplasm of breast, male CPT Code full sequence analysis and common duplication/deletion variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) 185delAG, 5385insC, 6174delT variants uncommon duplication/deletion variants BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant Page 4

5 BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant Molecular diagnostics; molecular isolation or extraction, each nucleic acid type (ie, DNA or RNA) Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA) Molecular diagnostics; enzymatic digestion, each enzyme treatment Molecular diagnostics; dot/slot blot production, each nucleic acid preparation Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation Molecular diagnostics; nucleic acid probe, each Molecular diagnostics; nucleic acid transfer (eg, Southern, Northern), each nucleic acid preparation Molecular diagnostics; amplification, target, each nucleic acid sequence Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure) Molecular diagnostics; reverse transcription Molecular diagnostics; mutation scanning, by physical properties (eg, single strand conformational polymorphisms [SSCP], heteroduplex, denaturing gradient gel electrophoresis [DGGE], RNA'ase A), single segment, each Molecular diagnostics; mutation identification by sequencing, single segment, each segment Molecular diagnostics; mutation identification by allele specific transcription, single segment, each segment Code range; mutation scanning or identification Molecular diagnostics; separation and identification by high resolution technique (eg, capillary electrophoresis), each nucleic acid preparation Molecular diagnostics; interpretation and report Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family HCPCS Code S0265 S3823 Genetic counseling, under physician supervision, each 15 minutes Three-mutation BRCA1 and BRCA2 analysis for susceptibility to breast and ovarian cancer in Ashkenazi individuals V. Policy History Policy Number: M.DIA Current Effective Date: 03/01/2012 Original Document Effective Date: 03/01/2012 Previous Revision Dates: None HCR_MPP Page 5